Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

Plasma biomarkers are promising tools for the early diagnosis of dementia and for monitoring its progression. In a population-based study, de Wolf et al. show that low amyloid-β42 and high NfL levels are associated, both independently and in combination, with an increased risk of dementia and Alzheimer’s disease.

[1]  Meike W. Vernooij,et al.  Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study , 2018, Alzheimer's Research & Therapy.

[2]  S. Hatano,et al.  Experience from a multicentre stroke register: a preliminary report. , 1976, Bulletin of the World Health Organization.

[3]  Wiro J. Niessen,et al.  Brain tissue volumes in relation to cognitive function and risk of dementia , 2010, Neurobiology of Aging.

[4]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[5]  Philip S. Insel,et al.  Plasma tau in Alzheimer disease , 2016, Neurology.

[6]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[7]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[8]  K. Blennow,et al.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.

[9]  J. Benichou,et al.  Choice of time‐scale in Cox's model analysis of epidemiologic cohort data: a simulation study , 2004, Statistics in medicine.

[10]  Michel Goedert,et al.  Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein , 2015, Science.

[11]  A. Hofman,et al.  Trajectories of decline in cognition and daily functioning in preclinical dementia , 2016, Alzheimer's & Dementia.

[12]  C. DeCarli,et al.  Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes , 2019, JAMA neurology.

[13]  M. Fornage,et al.  Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium , 2017, European Journal of Epidemiology.

[14]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[15]  J. Trojanowski,et al.  Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders , 2019, JAMA neurology.

[16]  J. Götz,et al.  Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.

[17]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[18]  O. Franco,et al.  The Rotterdam Study: 2018 update on objectives, design and main results , 2017, European Journal of Epidemiology.

[19]  J. Goudsmit,et al.  Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease , 2017, European Journal of Epidemiology.

[20]  C. Jack,et al.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.

[21]  W. M. van der Flier,et al.  Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals , 2018, Annals of clinical and translational neurology.

[22]  David M. Rissin,et al.  Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.

[23]  Albert Hofman,et al.  The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study , 2015, BMC Medicine.

[24]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[25]  K. Blennow,et al.  Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study , 2015, EBioMedicine.

[26]  M. Jorge Cardoso,et al.  Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia , 2016, Neurology.

[27]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[28]  Henrik Zetterberg,et al.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.

[29]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[30]  C. Masters,et al.  Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals , 2017, Alzheimer's & dementia.

[31]  Jun Yan.  Survival Analysis: Techniques for Censored and Truncated Data , 2004 .

[32]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[33]  A. Hofman,et al.  Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study , 2012, European Journal of Epidemiology.

[34]  Hang Su,et al.  Plasma neurofilament light chain levels in Alzheimer’s disease , 2017, Neuroscience Letters.

[35]  Philip S. Insel,et al.  Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease , 2016, EMBO molecular medicine.

[36]  H. Soininen,et al.  Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[37]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[38]  A. Hofman,et al.  Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. , 2014, Journal of Alzheimer's disease : JAD.

[39]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[40]  J. Weuve,et al.  2016 Alzheimer's disease facts and figures , 2016 .

[41]  Meike W. Vernooij,et al.  External validation of four dementia prediction models for use in the general community-dwelling population: a comparative analysis from the Rotterdam Study , 2018, European Journal of Epidemiology.

[42]  J. Trojanowski,et al.  Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. , 2017, Journal of Alzheimer's Disease.

[43]  P. Koudstaal,et al.  Lifetime risk of common neurological diseases in the elderly population , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[44]  Alzheimer's Disease Neuroimaging Initiative.  Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .

[45]  S. Iliffe,et al.  Dementia , 2009, BMJ : British Medical Journal.

[46]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[47]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[48]  J. Klein,et al.  Survival Analysis: Techniques for Censored and Truncated Data , 1997 .

[49]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[50]  J. Goudsmit.  The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain , 2016, European Journal of Epidemiology.

[51]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.